

REMARKS

Claims 1-3 were rejected under 35 U.S.C. § 102(e) as being anticipated by Gil et. al. Applicants respectfully disagree. Gil was filed on December 29, 2000. The present application is a continuation-in-part of United States Patent Application Serial No. 09/548,410, now U.S. Patent No. 6,313,172, which was filed on April 13, 2000. Since April 13, 2000 is before December 29, 2000, the rejection is improper unless the priority application does not support the claims. The presently claimed compound is disclosed in the priority application (see Formula 2 and claim 2). Claim 2 recites a use of the compound, and the specification describes the synthesis of the compound (see Example 1). Thus, the priority application fully supports the claims, and Gil is not prior art over the claims. Therefore, Applicants respectfully request that Examiner remove the rejection and pass the claims to issue.

Please charge Deposit Account 01-0885 for the extension fees and any other fees due in this case.

Respectfully submitted,

Date: February 9, 2007

/Brent A. Johnson/
Brent A. Johnson
Registration No. 51,851
Agent of Record
Telephone: 714/246-4348
Telecopier: 714/246-4249

Please address all correspondence and inquiries to:

Brent A. Johnson (T2-7H)
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Tel: 714.246.4348
Fax: 714.246.4249